Lung Caner study 1:
Study name:
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation
Eligibility:
Participants with locally advanced NSCLC with KRAS G12C mutation.
Treatment 1:
Adagrasib
Treatment 2:
Adagrasib plus Pembrolizumab
Pembrolizumab
Lung Caner study 2: (Completed recruitment)
Study name:
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Eligibility:
Patients with unresectable, locally advanced or metastatic NSCLC with KRAS G12C mutation and disease progression on or after treatment with a platinum-based regimen and an immune checkpoint inhibitor.
Treatment 1:
MRTX849
Treatment 2:
Docetaxel